With these remarks, our pioneer proof of concept of allele‐specific silencing for the most frequent DNM2 mutation responsible for AD‐CNM allows us to envision a treatment for this neuromuscular disorder and paves the way for the other CNM mutations as well as the other DNM2‐linked inherited diseases. This evidence concerns the gene DNM2 and Alzheimer disease.